Abstract: Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g.
Abstract: The invention disclosed a homogenous substantially alcohol free composition of Cyclosporin which comprises a Cyclosporin in a hydrophilic carrier medium comprising propylene glycol, esters of propylene glycol with C4 to C12 fatty acids and polyoxyethylene hydrogenated castor oils wherein the ingredients are present in the following ranges, Cyclosporin 1-25% w/w, Propylene Glycol 5-50% w/w, Esters of Propylene Glycol with C4 to C12 fatty acids 10-40% w/w and Polyoxyethylene hydrogenated Castor oils 25-60% w/w.
Abstract: A Novel composition and a method for treating anorectal diseases including hemorrhoids and colonic diseases with long term effectiveness and low prolapse rates is disclosed. The compositions are water soluble and can be uniformly applied in the affected region. The composition comprises Flavonoidal constituents which possess anti-inflammatory properties.
Type:
Grant
Filed:
April 21, 1997
Date of Patent:
January 12, 1999
Assignees:
Panacea Biotech Limited, University Institute of Pharmaceutical Sciences